Literature DB >> 28716827

Galectin-1-Driven Tolerogenic Programs Aggravate Yersinia enterocolitica Infection by Repressing Antibacterial Immunity.

Roberto C Davicino1, Santiago P Méndez-Huergo2, Ricardo J Eliçabe1, Juan C Stupirski2, Ingo Autenrieth3, María S Di Genaro1, Gabriel A Rabinovich4,5.   

Abstract

Yersinia enterocolitica is an enteropathogenic bacterium that causes gastrointestinal disorders, as well as extraintestinal manifestations. To subvert the host's immune response, Y. enterocolitica uses a type III secretion system consisting of an injectisome and effector proteins, called Yersinia outer proteins (Yops), that modulate activation, signaling, and survival of immune cells. In this article, we show that galectin-1 (Gal-1), an immunoregulatory lectin widely expressed in mucosal tissues, contributes to Y. enterocolitica pathogenicity by undermining protective antibacterial responses. We found higher expression of Gal-1 in the spleen and Peyer's patches of mice infected orogastrically with Y. enterocolitica serotype O:8 compared with noninfected hosts. This effect was prevented when mice were infected with Y. enterocolitica lacking YopP or YopH, two critical effectors involved in bacterial immune evasion. Consistent with a regulatory role for this lectin during Y. enterocolitica pathogenesis, mice lacking Gal-1 showed increased weight and survival, lower bacterial load, and attenuated intestinal pathology compared with wild-type mice. These protective effects involved modulation of NF-κB activation, TNF production, and NO synthesis in mucosal tissue and macrophages, as well as systemic dysregulation of IL-17 and IFN-γ responses. In vivo neutralization of these proinflammatory cytokines impaired bacterial clearance and eliminated host protection conferred by Gal-1 deficiency. Finally, supplementation of recombinant Gal-1 in mice lacking Gal-1 or treatment of wild-type mice with a neutralizing anti-Gal-1 mAb confirmed the immune inhibitory role of this endogenous lectin during Y. enterocolitica infection. Thus, targeting Gal-1-glycan interactions may contribute to reinforce antibacterial responses by reprogramming innate and adaptive immune mechanisms.
Copyright © 2017 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28716827     DOI: 10.4049/jimmunol.1700579

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

1.  Glycosylation-dependent galectin-receptor interactions promote Chlamydia trachomatis infection.

Authors:  Agustin L Lujan; Diego O Croci; Julián A Gambarte Tudela; Antonella D Losinno; Alejandro J Cagnoni; Karina V Mariño; María T Damiani; Gabriel A Rabinovich
Journal:  Proc Natl Acad Sci U S A       Date:  2018-06-11       Impact factor: 11.205

Review 2.  Galectins as potential therapeutic targets in STIs in the female genital tract.

Authors:  Agustin L Lujan; Diego O Croci; Gabriel A Rabinovich; Maria T Damiani
Journal:  Nat Rev Urol       Date:  2022-02-01       Impact factor: 14.432

3.  Effects of bilateral early breast sucking and unilateral early breast sucking within 2 h after delivery on lactation, breast distending pain and postpartum lochia.

Authors:  Wei Shao; Bingxin Zheng; Guoxia Zhou; Lin Sun
Journal:  Am J Transl Res       Date:  2021-11-15       Impact factor: 4.060

Review 4.  TrkB-Target Galectin-1 Impairs Immune Activation and Radiation Responses in Neuroblastoma: Implications for Tumour Therapy.

Authors:  Katharina Batzke; Gabriele Büchel; Wiebke Hansen; Alexander Schramm
Journal:  Int J Mol Sci       Date:  2018-03-02       Impact factor: 5.923

Review 5.  All Yersinia Are Not Created Equal: Phenotypic Adaptation to Distinct Niches Within Mammalian Tissues.

Authors:  Kimberly M Davis
Journal:  Front Cell Infect Microbiol       Date:  2018-08-03       Impact factor: 5.293

Review 6.  Galectin-1 as an Emerging Mediator of Cardiovascular Inflammation: Mechanisms and Therapeutic Opportunities.

Authors:  Ignacio M Seropian; Germán E González; Sebastián M Maller; Daniel H Berrocal; Antonio Abbate; Gabriel A Rabinovich
Journal:  Mediators Inflamm       Date:  2018-11-05       Impact factor: 4.711

7.  Control of intestinal inflammation by glycosylation-dependent lectin-driven immunoregulatory circuits.

Authors:  Luciano G Morosi; Anabela M Cutine; Alejandro J Cagnoni; Montana N Manselle-Cocco; Diego O Croci; Joaquín P Merlo; Rosa M Morales; María May; Juan M Pérez-Sáez; María R Girotti; Santiago P Méndez-Huergo; Betiana Pucci; Aníbal H Gil; Sergio P Huernos; Guillermo H Docena; Alicia M Sambuelli; Marta A Toscano; Gabriel A Rabinovich; Karina V Mariño
Journal:  Sci Adv       Date:  2021-06-18       Impact factor: 14.136

Review 8.  Clinical Relevance of Galectin-1 and Galectin-3 in Rheumatoid Arthritis Patients: Differential Regulation and Correlation With Disease Activity.

Authors:  Santiago P Mendez-Huergo; Pablo F Hockl; Juan C Stupirski; Sebastián M Maller; Luciano G Morosi; Nicolás A Pinto; Ana M Berón; Jorge L Musuruana; Gustavo G Nasswetter; Javier A Cavallasca; Gabriel A Rabinovich
Journal:  Front Immunol       Date:  2019-01-09       Impact factor: 7.561

Review 9.  Utilization of Galectins by Pathogens for Infection.

Authors:  Diyoly Ayona; Pierre-Edouard Fournier; Bernard Henrissat; Benoit Desnues
Journal:  Front Immunol       Date:  2020-08-19       Impact factor: 7.561

Review 10.  Galectins in Chagas Disease: A Missing Link Between Trypanosoma cruzi Infection, Inflammation, and Tissue Damage.

Authors:  Carolina V Poncini; Alejandro F Benatar; Karina A Gomez; Gabriel A Rabinovich
Journal:  Front Microbiol       Date:  2022-01-03       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.